Amgen Inc. (AMGN) Q2 Profit Rises

PARAGRAPH 1 --- What happened: Amgen Inc. (AMGN) reported Q2 2022 earnings on August 3, 2022, with profits rising to $2.38 billion, or $4.37 per share, up from $1.43 billion, or $2.65 per share, in Q2 2021. The company's sales increased by 9% year-over-year, driven by demand for Repatha, Evenity, and rare disease medications. Amgen also raised its full-year outlook and discontinued development of an early-stage weight loss drug, AMG 513.

PARAGRAPH 2 --- Market impact: The positive earnings report and increased outlook boosted Amgen's stock price, benefiting investors. The company's strong performance in the rare disease and cholesterol drug segments positively impacted the biotechnology sector. However, the discontinuation of AMG 513 may have a minor impact on the weight loss drug development space.

PARAGRAPH 3 --- What to watch next: Investors should monitor Amgen's Q3 earnings release, scheduled for October 27, 2022, to see if the company maintains its positive momentum. Additionally, regulatory decisions on Amgen's experimental weight loss drug, MariTide, will be crucial for the company's future growth in this therapeutic area.